Difference between revisions of "R-FCM + maintenance R"
(New page: == Regimen == R-FCM followed by Rituximab 375 mg/m2 iv qw x 4 doses at 3 and 9 months == References == [http://www.bloodjournal.org/cgi/content/abstract/108/13/4003 Forstpointner R e...)
m (1 revision)
Latest revision as of 02:18, 7 February 2012
R-FCM followed by Rituximab 375 mg/m2 iv qw x 4 doses at 3 and 9 months
Forstpointner R et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003